Literature DB >> 24362499

Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports.

B Schulze1, M Meissner, M Wolter, C Rödel, C Weiss.   

Abstract

BACKGROUND: Besides radiotherapy (RT) and surgery, the introduction of BRAF inhibitors like vemurafenib has provided new opportunities for treatment of patients with metastasized malignant melanomas. RT and vemurafenib are being increasingly used concurrently, although little is known about the potential side effects of this combination. Vemurafenib is known to cause severe cutaneous skin reactions such as phototoxicity and evidence is accumulating that RT may further enhance these side effects. PATIENTS AND METHODS: We report two cases of unusual skin reactions occurring during and after treatment with a combination of vemurafenib and whole-brain irradiation in patients with cerebral metastases arising from malignant melanomas.
RESULTS: One case report describes excessive acute radiodermatitis which arose during whole-brain irradiation in combination with vemurafenib. The second describes a late skin reaction occurring approximately 30 days after completion of RT.
CONCLUSION: These two case reports show that combination of both treatment modalities is possible, but requires close monitoring of patients and good interdisciplinary collaboration.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24362499     DOI: 10.1007/s00066-013-0474-3

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  23 in total

1.  Ultraviolet A and photosensitivity during vemurafenib therapy.

Authors:  Reinhard Dummer; Jeannine Rinderknecht; Simone M Goldinger
Journal:  N Engl J Med       Date:  2012-02-02       Impact factor: 91.245

2.  Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival.

Authors:  M H Amer; M Al-Sarraf; L H Baker; V K Vaitkevicius
Journal:  Cancer       Date:  1978-08       Impact factor: 6.860

3.  Outcome after whole brain radiotherapy alone in intracranial leptomeningeal carcinomatosis from solid tumors.

Authors:  C Gani; A C Müller; F Eckert; C Schroeder; B Bender; G Pantazis; M Bamberg; B Berger
Journal:  Strahlenther Onkol       Date:  2012-01-11       Impact factor: 3.621

4.  Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.

Authors:  J H Sampson; J H Carter; A H Friedman; H F Seigler
Journal:  J Neurosurg       Date:  1998-01       Impact factor: 5.115

5.  Determinants of outcome in melanoma patients with cerebral metastases.

Authors:  K M Fife; M H Colman; G N Stevens; I C Firth; D Moon; K F Shannon; R Harman; K Petersen-Schaefer; A C Zacest; M Besser; G W Milton; W H McCarthy; J F Thompson
Journal:  J Clin Oncol       Date:  2004-04-01       Impact factor: 44.544

6.  Vemurafenib and radiosensitization.

Authors:  Lise Boussemart; Catherine Boivin; Joël Claveau; Yun Gan Tao; Gorana Tomasic; Emilie Routier; Christine Mateus; Eric Deutsch; Caroline Robert
Journal:  JAMA Dermatol       Date:  2013-07       Impact factor: 10.282

7.  Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases.

Authors:  L Dziggel; B Segedin; N H Podvrsnik; I Oblak; S E Schild; D Rades
Journal:  Strahlenther Onkol       Date:  2013-03-23       Impact factor: 3.621

8.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

9.  RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

Authors:  Fei Su; Amaya Viros; Carla Milagre; Kerstin Trunzer; Gideon Bollag; Olivia Spleiss; Jorge S Reis-Filho; Xiangju Kong; Richard C Koya; Keith T Flaherty; Paul B Chapman; Min Jung Kim; Robert Hayward; Matthew Martin; Hong Yang; Qiongqing Wang; Holly Hilton; Julie S Hang; Johannes Noe; Maryou Lambros; Felipe Geyer; Nathalie Dhomen; Ion Niculescu-Duvaz; Alfonso Zambon; Dan Niculescu-Duvaz; Natasha Preece; Lídia Robert; Nicholas J Otte; Stephen Mok; Damien Kee; Yan Ma; Chao Zhang; Gaston Habets; Elizabeth A Burton; Bernice Wong; Hoa Nguyen; Mark Kockx; Luc Andries; Brian Lestini; Keith B Nolop; Richard J Lee; Andrew K Joe; James L Troy; Rene Gonzalez; Thomas E Hutson; Igor Puzanov; Bartosz Chmielowski; Caroline J Springer; Grant A McArthur; Jeffrey A Sosman; Roger S Lo; Antoni Ribas; Richard Marais
Journal:  N Engl J Med       Date:  2012-01-19       Impact factor: 91.245

10.  The role of BRAF V600 mutation in melanoma.

Authors:  Paolo A Ascierto; John M Kirkwood; Jean-Jacques Grob; Ester Simeone; Antonio M Grimaldi; Michele Maio; Giuseppe Palmieri; Alessandro Testori; Francesco M Marincola; Nicola Mozzillo
Journal:  J Transl Med       Date:  2012-07-09       Impact factor: 5.531

View more
  17 in total

1.  BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study.

Authors:  Panagiotis Mastorakos; Zhiyuan Xu; James Yu; Judith Hess; Jack Qian; Ajay Chatrath; Davis G Taylor; Douglas Kondziolka; Ronald Warnick; Veronica Chiang; Jason Sheehan
Journal:  Neurosurgery       Date:  2019-04-01       Impact factor: 4.654

2.  Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia.

Authors:  Nina Lang; Florian Sterzing; Alexander H Enk; Jessica C Hassel
Journal:  Strahlenther Onkol       Date:  2014-06-28       Impact factor: 3.621

3.  Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries.

Authors:  S G C Kroeze; C Fritz; L Basler; E Gkika; T B Brunner; A L Grosu; M Guckenberger
Journal:  Strahlenther Onkol       Date:  2019-02-08       Impact factor: 3.621

Review 4.  Managing the skin toxicities from new melanoma drugs.

Authors:  John C Mavropoulos; Timothy S Wang
Journal:  Curr Treat Options Oncol       Date:  2014-06

5.  Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases.

Authors:  Yingmei Li; Wenying Pan; Ian D Connolly; Sunil Reddy; Seema Nagpal; Stephen Quake; Melanie Hayden Gephart
Journal:  J Neurooncol       Date:  2016-03-09       Impact factor: 4.130

6.  Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors.

Authors:  Maikel Verduin; Jaap D Zindler; Hanneke M A Martinussen; Rob L H Jansen; Sander Croes; Lizza E L Hendriks; Danielle B P Eekers; Ann Hoeben
Journal:  Oncologist       Date:  2017-02-06

7.  LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases.

Authors:  Kamran A Ahmed; Jessica M Freilich; Sarah Sloot; Nicholas Figura; Geoffrey T Gibney; Jeffrey S Weber; Siriporn Sarangkasiri; Prakash Chinnaiyan; Peter A Forsyth; Arnold B Etame; Nikhil G Rao
Journal:  J Neurooncol       Date:  2014-12-18       Impact factor: 4.130

8.  Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy.

Authors:  Ricarda Merten; Markus Hecht; Marlen Haderlein; Luitpold Distel; Rainer Fietkau; Lucie Heinzerling; Sabine Semrau
Journal:  Strahlenther Onkol       Date:  2014-06-26       Impact factor: 3.621

Review 9.  Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).

Authors:  Christopher J Anker; Kenneth F Grossmann; Michael B Atkins; Gita Suneja; Ahmad A Tarhini; John M Kirkwood
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-06-01       Impact factor: 7.038

10.  Hedgehog pathway inhibitor in combination with radiation therapy for basal cell carcinomas of the head and neck : First clinical experience with vismodegib for locally advanced disease.

Authors:  Björn Schulze; Markus Meissner; Shahram Ghanaati; Iris Burck; Claus Rödel; Panagiotis Balermpas
Journal:  Strahlenther Onkol       Date:  2015-10-08       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.